Tri-Institutional TB Research Unit: Persistence and Latency

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 3U19AI111143-06S1

Grant search

Key facts

  • Disease

  • Start & end year

  • Known Financial Commitments (USD)

  • Funder

    National Institutes of Health (NIH)
  • Principle Investigator

  • Research Location

    United States of America, Americas
  • Lead Research Institution

    Weill Cornell Medicine - Cornell University
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory


  • Special Interest Tags


  • Study Subject


  • Clinical Trial Details


  • Broad Policy Alignment


  • Age Group


  • Vulnerable Population


  • Occupations of Interest



The COVID-19 pandemic has now spread from high- and middle-income countries to low-income countries,including Haiti and Tanzania. The natural history of COVID-19 is unknown in low-income countries. Wepropose to study a combined cohort of 3,054 adults in Haiti and Tanzania to determine the attack rate ofSARS-CoV-2 infection and severe COVID-19, to examine interactions with HIV infection, pulmonarytuberculosis, and hypertension in populations of African descent, and to determine long term cardiaccomplications of COVID-19. Cornell University has collaborated with the Groupe Haitien d'Etude du Sarcomede Kaposi et des Infections Opportunistes (GHESKIO) in Haiti for 38 years and for 15 years with the MwanzaIntervention Trials Unit (MITU) in Tanzania. The proposed emergency supplement leverages thesecollaborations and four established NIH-supported cohorts, which have already been enrolled, to addressNIAID priority areas. The specific aims are:1.To determine the incidence proportion of SARS-CoV-2 infection and the attack rate and risk factorsfor severe COVID-19, in well characterized cohorts of 3,054 adults from low-income communities inHaiti and Tanzania. Starting May 1, 2020 we will conduct monthly telephone interviews with the 3,054participants who are in active follow-up to record symptoms of COVID-19 during the pandemic. Participants willalso be encouraged to telephone us if they develop new symptoms. We have cell phone numbers for allcohort participants and have established procedures for telephone communication. We will also review hospitalrecords, perform verbal autopsies, and grade severity of COVID-19. We have banked sera from all participantscollected in 2016-2019. In September-November 2020 and again in March-May 2021, we will collect follow-upsera and perform serologic testing for the presence of anti-SARS-CoV-2 IgG antibodies. We will determine theodds for development of severe COVID-19 in participants who had HIV, TB, and hypertension.2. To determine the cardiac complications of SARS-CoV-2 infection in 1,909 adults with known baselinecardiac function. In 1,909 patients who previously had baseline EKGs and echocardiograms (2016-2019), wewill repeat cardiac echo and EKG in 2021 to quantify the odds for development of incident left ventricularsystolic dysfunction in those who did and did not become SARS-CoV-2 infected. LV function will be quantifiedby global longitudinal strain. We will also determine incidence of right ventricular systolic dysfunction,pulmonary hypertension and segmental wall motion abnormalities by echocardiogram, and new Q-waves andother abnormalities on EKG.Defining viral infection rates and natural history in low-income countries will be critical for future preventioninterventions. Determining risk for people with HIV, TB, and hypertension will improve their care andprevention. Understanding cardiac sequelae of SARS-CoV-2 will improve care for COVID-19 survivors.